Title
Risk of tuberculosis with the use of anti-TNF medications in psoriasis: incidence, screening and management

Permalink
https://escholarship.org/uc/item/8s09h73j

Journal
Dermatology Online Journal, 20(8)

Authors
Kasiraman, Vijayalakshmi
Atwan, Ausama A
Durojaiye, Oyewole Chris
et al.

Publication Date
2014

DOI
10.5070/D3208023525

Copyright Information
Copyright 2014 by the author(s). This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at https://creativecommons.org/licenses/by-nc-nd/4.0/

Peer reviewed
Review

Risk of tuberculosis with the use of anti-TNF medications in psoriasis: incidence, screening and management

Vijayalakshmi Kasiraman¹, Ausama A Atwan², Oyewole Chris Durojaiye³, Manju Kalavala⁴, Vincent Piguet²

Dermatology Online Journal 20 (8): 2

¹Department of Dermatology, Royal Oman Police Hospital, Muscat, Oman.
²Department of Dermatology and Wound Healing, Cardiff University, Cardiff, UK.
³Department of Microbiology, University Hospital of Wales, Cardiff, UK.
⁴Department of Dermatology, University Hospital of Wales, Cardiff, UK.

Correspondence:

Dr Ausama A Atwan
3rd Floor, Glamorgan House
Department of Dermatology and Wound Healing
Heath Park
Cardiff University, School of Medicine
Cardiff
CF14 4XN
UK
Tel: 0044(0)2920745870
Fax: 0044(0)2920744312
Email: AbouAtwanAA@cardiff.ac.uk

Abstract

Tumor necrosis factor (TNF) plays an important role in containing mycobacterial infections. With the rapidly increasing role of TNF inhibitors in dermatology, tuberculosis (TB) is becoming an important and worrisome concern to dermatologists. This paper aims to provide a comprehensive review on the incidence of TB in patients treated with anti-TNF, the variety of TB screening methods, and management of these cases. Various national recommendations have been highlighted. The monoclonal antibodies, infliximab and adalimumab, appear to be more associated with the risk of TB reactivation than the soluble receptor etanercept. Tuberculosis associated with TNF inhibitors, in contrast to classical TB, is more likely to be disseminated, atypical, extra pulmonary, and life threatening. Vigilance for typical and atypical presentations of active TB is mandatory until the end of therapy. Although tuberculin standard test (TST) has been the gold standard for screening of latent TB infection (LTBI) for close to a century, it has several inadequacies and may be unreliable in patients with widespread psoriasis. Interferon gamma release assays (IGRAs) with better diagnostic specificity and sensitivity are a promising adjunct to diagnose LTBI at present. Although appropriate screening and treatment of LTBI will lower the risk of reactivation to a great extent, no chemoprophylactic regimen is fully protective.

Keywords: Psoriasis, tuberculosis, anti-TNF, biologics, screening

Introduction

Tumor necrosis factor alpha (TNF-α) is a master cytokine in the pathogenesis of psoriasis. By binding to its specific p55 and p75 receptors, it triggers an inflammatory cytokine cascade that inhibits keratinocyte apoptosis, induces keratinocyte
hyperproliferation in the skin, and causes inflammation and destruction in the joints [1]. TNF-α levels are elevated in psoriatic plaques, serum, and synovial fluid of patients with psoriasis and the levels correlate positively with disease severity [1-3]. Under physiological conditions, TNF-α plays a crucial role in the formation and maintenance of granulomas that contain mycobacterial infections, which cannot otherwise be eradicated by the host defence mechanisms [4]. In tuberculosis (TB), the bacilli are sequestered within granulomas where they are contained in a viable but dormant state via TNF mediated activation of antigen specific T-cells, recruitment of macrophages, and secretion of inflammatory cytokines. This important role of TNF-α in host defences against TB has been demonstrated in animal models in which inhibition of TNF-α led to loss of ability to control primary infection, breakdown of granulomas and release of mycobacteria, and rapid progression to active disease [4]. In humans, studies based on post-marketing surveillance of adverse drug reactions and biologic registries have shown a consistent risk of reactivation of latent tuberculosis in individuals being treated with TNF-α blockade therapies [5-9].

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Globally, it is second only to the human immunodeficiency virus (HIV) as the leading infectious cause of death. According to the last WHO estimates, 8.7 million new cases of TB and 1.4 million TB deaths occurred in the year 2011 [10]. Following primary infection, 95% of patients are able to effectively contain the bacterium in a state of latency by mediating a robust cell-mediated immune response. These individuals are then said to have latent tuberculosis infection (LTBI) and are asymptomatic and non-infectious; they mostly remain free of disease for their lifetimes unless the immunological balance between the host and pathogen is perturbed in some way [4,11]. About one-third of the world's population is latently infected, with a 5-10% lifetime risk of progression from LTBI to active disease [12]. Factors that drive progression include HIV infection, diabetes, chronic renal failure, silicosis, organ transplants, and immunosuppressive medications such as systemic corticosteroids and TNF antagonists [4,11,12].

Until as recently as a decade ago, diagnosis and treatment of non-cutaneous TB were outside the realm of regular dermatological practice. However, with the advent of anti-TNF therapies for psoriasis, patients treated with these drugs have become a new high risk group for developing TB and it is now imperative for dermatologists to have in-depth knowledge and understanding of the immunopathogenesis, clinical presentation, screening methods, and management of TB in this group of patients; this papers aims to provide summaries of these. PubMed, the Cochrane library, Google Scholar, and Medline via Ovid (1946 to August 2013) were searched using the keywords: tuberculosis, biologics, screening and tumour necrosis factor. The search was limited to papers in the English language and individual search hits were combined with “and”. Reference lists of relevant papers were also searched for related studies resulting in a total of 61 records.

Incidence of tuberculosis with anti-TNF therapy

Data from a number of studies and biologic registries, mostly in the rheumatoid arthritis (RA) population, have tried to establish the incidence of TB associated with TNF inhibitor therapy (Table 1). Based on data from the BIOBADASER, a national biologics registry established by the Spanish society of Rheumatology, Gomez-Reino et al [7] reported an extremely high TB incidence rate (IR) in patients treated with infliximab in the year 2000, prior to implementation of screening recommendations (IR= 1893 per 100,000 patient-years vs. only 21/100,000 patient-years in the general population) [risk ratio (RR) = 90.1 (95% CI 58.8 to 146.0)]. Similarly, Tubach et al [8] reported 69 cases of TB in patients treated with infliximab, adalimumab and etanercept between 2004 and 2006, translating to an IR of 116.7/100,000 patient-years (95% CI 10.6 to 222.9); this is about 12 times greater than the rate in the general UK population [8].

Recently, Dixon et al [9] carried out a prospective observational study using the British Society for Rheumatology Biologics Registry (BSRBR) to explore drug-specific risk of TB in patients treated with anti-TNF between 2001 and 2008. A total of 39 cases of TB associated with the three TNF inhibitors were identified translating to an IR of 118/100,000 patient-years (95% CI 84 to 160); this is over 8 times greater than the rate in the general UK population [8].

Table 1. Major Studies Reporting Tuberculosis Associated With TNF-α Inhibitor Therapy in RA

<table>
<thead>
<tr>
<th>AUTHOR</th>
<th>COUNTRY</th>
<th>SOURCE OF DATA</th>
<th>TB IR with anti-TNF /100,000 PATIENT-YEARS (95% CI)</th>
<th>TB IR in RA POPULATION / 100,000 PATIENT-YEARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keane, 2001 [5]</td>
<td>USA and Europe</td>
<td>FDAAERS</td>
<td>Etanercept: -</td>
<td>Infliximab: 24.4 (95% CI 0.6 - 34.0)</td>
</tr>
<tr>
<td>Mohan, 2004 [58]</td>
<td>USA</td>
<td>FDAAERS</td>
<td>10</td>
<td>-</td>
</tr>
<tr>
<td>Author</td>
<td>Country</td>
<td>Database/Registry</td>
<td>TB Incidence Rate</td>
<td>95% CI</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
<td>----------------------------------------</td>
<td>-------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Wallis, 2004</td>
<td>USA</td>
<td>FDAAERS</td>
<td>28</td>
<td>-</td>
</tr>
<tr>
<td>Wolfe, 2004</td>
<td>USA</td>
<td>National Database for Rheumatic Diseases</td>
<td>-</td>
<td>52.5 (95% CI 14.3 - 134.4)</td>
</tr>
<tr>
<td>Askling, 2005</td>
<td>Sweden</td>
<td>Swedish registry</td>
<td>80</td>
<td>145</td>
</tr>
<tr>
<td>Gomez –Reino, 2007</td>
<td>Spain</td>
<td>Spanish register BIOBADASER</td>
<td>114</td>
<td>383</td>
</tr>
<tr>
<td>Tubach, 2009</td>
<td>France</td>
<td>French register RATIO</td>
<td>9.3</td>
<td>187.5</td>
</tr>
<tr>
<td>Dixon, 2010</td>
<td>UK</td>
<td>British registry BSRBR</td>
<td>39 (95% CI 13 -92)</td>
<td>136 (95% CI 68 - 244)</td>
</tr>
</tbody>
</table>

TB: Tuberculosis; IR: incidence rate; TNF: tumour necrosis factor; 95% CI: confidence interval; RA: Rheumatoid arthritis; FDAAERS: Food and Drug Administration Adverse Events Reporting System; RATIO: French Research Axed on Tolerance to Biotherapies; BSRBR: British Society for Rheumatology Biologics Registry

Although the risk of reactivation is common to all TNF inhibitors, the monoclonal antibodies infliximab and adalimumab appear to portend a much higher risk compared to the soluble TNF receptor etanercept [5,8,9,13,14] (Table 1). In a large review based on cases reported voluntarily to the Food and Drug Administration Adverse Events Reporting System (FDAAERS) between January 1998 and September 2002, Wallis et al [13,14] reported higher rates of granulomatous infections associated with infliximab (54/100,000) than with etanercept (28/100,000) in cases restricted to the United States. However, pharmaco-vigilance based on voluntary reporting is prone to inherent flaws like physician underreporting and reporter bias. Also, other differences such as the local prevalence rates of TB, pattern of drug use (preferential use of infliximab in Europe where TB prevalence rates are higher), severity of the underlying disease, concomitant medications and medical comorbidities may all potentially confound the analysis of differential risks between these drugs [11]. A recent analysis of data from the British Society for Rheumatology Biologics Registry (BSRBR) [9] controlled for these confounders and showed high tuberculosis IR of 144 /100,000 patient-years for adalimumab (95% CI 72 to 258) and 136 /100,000 patient-years for infliximab (95% CI 68 to 244) vs. only 39 /100,000 patient-years for etanercept (95% CI 13 to 92). Likewise, data analysis from the French registry RATIO [8] also controlled for differences and showed that most cases of TB were associated with the use of adalimumab [SIR = 29.3 (95% CI 20.3-42.4; p< 0.0001)] and infliximab [SIR= 18.6 (95% CI 13.4 to 25.8; p< 0.0001)] rather than etanercept [SIR=1.8 (95% CI 0.7 to 4.3; p= 0.20)]. Although the exact mechanisms remain unclear, differences in the pharmacodynamic properties and mechanism of action of these drugs have been proposed to explain this disparity [11].

Although this large body of epidemiological evidence supports the biological plausibility that LTBI reactivation can occur with TNF-α inhibition, most of this data relates to the use of these drugs in RA, which itself is associated with an increased risk of TB. Also, drugs like methotrexate and corticosteroids used in the management of RA may further contribute to the immunosuppressed state [15, 16]. Currently, the proportion of risk that stems from the immunological disease itself, the concomitant medications or the synergy between these drugs, rather than the TNF inhibitor therapy itself is unknown [16,17]. Whereas there have been anecdotal reports of TB associated with the use of methotrexate in RA and psoriasis, this risk has not been confirmed by any large studies [18-20]. On the other hand, prolonged use of corticosteroids at doses 15-20 mg/day has been shown to increase the risk of tuberculosis independent of other risk factors [21-23]. Although dermatologists should benefit from the rheumatology experience, extrapolating this data to patients with psoriasis may overestimate the potential risks because TNFα inhibitors are typically given as monotherapy in psoriasis. This risk of TB activation with anti-TNF monotherapy in psoriasis was examined in some case reports [24-26], which found that active cases of TB, although few in number, were continuously reported with the use of these drugs in psoriasis. Another analysis of the risks associated with TNF inhibitors in psoriasis reported a lifetime risk of tuberculosis of 0-17% in patients using TNF inhibitors versus 0.3% in those without [27].

**Development of active TB in patients undergoing anti-TNF-α therapy**

Unlike TB in immunocompetent individuals, TB associated with anti-TNF therapies is often atypical, extra pulmonary, and disseminated [4, 5,11]. The diagnosis is commonly delayed owing to the altered presentation and the disease may initially be refractory to treatment because of the lingering of anti-TNFα in the system [28]. All these factors confer a high degree of morbidity and associated mortality in these patients. In one study [5], over half of the reported cases had extra-pulmonary disease...
and in more than a quarter it was disseminated. Additionally, most cases associated with TNFα inhibitors occurred in close proximity to the initiation of therapy and progressed rapidly, suggesting reactivation of latent infection rather than new disease. The estimated median time from initiation of therapy to diagnosis of TB is 3 months for infliximab, 4-6 months for adalimumab, and 11.5 months for etanercept [28]. Nevertheless, TB occurred in a few patients 7.1 - 13.9 months after discontinuation of mononuclear antibodies infliximab (n=3) and adalimumab (n=1) [8].

**Screening for latent TB infection (LTBI)**

Considering the high risk of reactivation of LTBI, fulminant course of TB disease, and morbidity and mortality associated with anti-TNF therapies, screening for tuberculosis before the initiation of these drugs is mandatory and should be considered the standard of care [11,28,29]. Screening should include a detailed medical history, chest X-ray, and tuberculin skin test (TST) and/or interferon-gamma release assay (IGRA) [29,30]. The history should include assessment of risk factors for tuberculosis, such as birth or residence in a country of high TB prevalence, recent travel to an area of high TB prevalence, recognised exposure to a patient with pulmonary TB, residence in a congregate setting (homeless shelters, prison, chronic care facilities, drug abusers), history of drug abuse, employment in facilities that treat tuberculosis, and any past history of adequately or inadequately treated tuberculosis [29,30]. Patients should also be questioned about symptoms like persistent cough, weight loss, night sweats, and fever to rule out active tuberculosis.

Several reports have documented the beneficial impact of screening and treatment of LTBI before anti-TNF therapy. Gomez-Reino et al [31] reported a fall in the tuberculosis IR from 472/100,000 patient-years (95%CI 384 to 642) to 43/100,000 patient-years (95% CI 11 to 175) when national screening recommendations were followed, compared to a 7-fold increase when they were not. The impact of screening has also been reported from Europe and North America [32] and Spain [33], which reported 85% and 83% decreases in the incidence of TB associated with adalimumab and infliximab therapy, respectively, following implementation of official recommendations on screening and treatment [incidence risk ratio (IRR) 1.0, (95% CI 0.02 to 8.2)].

**Tuberculin skin test (TST)**

The standard TST, using the Mantoux technique, involves the intradermal inoculation of 0.1ml of tuberculin-purified protein derivative (PPD), a crude mixture of more than 200 M. tuberculosis proteins, on the inner surface of the forearm. This stimulates a delayed (type IV) hypersensitivity reaction mediated by T-lymphocytes, leading to skin induration within 48 to 72 hours and rarely blistering and necrosis [11,21,34]. The greater the reaction, the more likely it is that an individual is infected with M. tuberculosis. Mantoux technique has largely replaced multiple-puncture methods such as the Tine test and Heaf test which are often unreliable because it is not possible to accurately control the amount of tuberculin.

The Mantoux test is read by measuring the size of induration (not erythema) 48 to 72 hours after intradermal injection [11]. Results read after this time period may be less reliable. A TST with ≥15 mm of induration is considered positive in healthy individuals with no risk for TB [21]. However, according to the National Psoriasis Foundation (NPF) recommendations, in patients considered for anti-TNF therapy, an induration of 5mm or more should be interpreted as positive and preventive chemotherapy initiated if there are no epidemiological risk factors for tuberculosis [30]. Vesiculation, ulceration, and necrosis may occur with active infection or infection that has been treated in the past [11].

Although the TST is the most widely used tool to detect tuberculosis infections, it has several limitations. False negative reactions may occur with advanced immunosuppression, live viral vaccination, some viral infections, and improper tuberculin handling [11,35]. Further, because many of the antigens in PPD cross-react with environmental mycobacteria and the BCG vaccine strain, false positive reactions may occur in BCG vaccinated individuals and those with non-tuberculous mycobacteriosis (NTM), resulting in poor specificity [11,12,34]. In addition, the logistical inconvenience of multiple visits, operator variability in the administering and reading of the test, and the lack of a standard value at which TST is considered positive are factors that limit its usefulness.

In psoriasis, the TST may be particularly unreliable and may overestimate the incidence of LTBI because the proinflammatory state of the skin results in enhanced immune responses and false positive TST reactions [36-38]. In an attempt to evaluate the effect of psoriasis on TST results, Tsouri et al [36] compared TST results in consecutive dermatology and internal medicine patients. Patients with psoriasis had significantly larger TST reactions compared to internal medicine patients (p< 0.0001) and were more likely to be treated for latent infection. TST was also found to correlate positively with PASI score [36]. These findings were reflected in another study by Basukkas et al [37] who showed that patients with psoriasis were likely to be overdiagnosed and overtreated for LTBI than demographically matched patients with inflammatory bowel disease when evaluated by TST. Furthermore, TST may pose special challenges in patients with widespread skin diseases like psoriasis, in which it may be impossible to find lesion free skin appropriate for TST testing [38].
Interferon-gamma release assay (IGRA):

TST was the only commercially available immunologic test for the diagnosis of LTBI for close to a century [35]. However, over the last decade, in vitro whole blood tests that measure the production of interferon gamma (INF-γ) by T-cells in response to highly specific M. tuberculosis proteins, the interferon gamma release assays (IGRAs), have been approved by the FDA as alternative diagnostic aids for M. tuberculosis infections [12,35]. The QuantiFERON-TB test (QFT) and the QuantiFERON-TB Gold Test (QFT-G) were the earliest IGRAs approved by the FDA [12]. Currently, the two commercially available IGRAs in many countries are the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay and T. SPOT.TB assay [12] (Table 2).

Table 2. FDA approved interferon gamma release assays (IGRAS) for the diagnosis of LTBI [12]

<table>
<thead>
<tr>
<th>TEST</th>
<th>ASSAY FORMAT</th>
<th>MANUFACTURER</th>
<th>FDA APPROVAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>QuantiFERON -TB test (QFT)</td>
<td>ELISA</td>
<td>Cellestis, Carnegie, Australia</td>
<td>2001</td>
</tr>
<tr>
<td>QuantiFERON-TB Gold test (QFT-G)</td>
<td>ELISA</td>
<td>Cellestis, Carnegie, Australia</td>
<td>2005</td>
</tr>
<tr>
<td>QuantiFERON-TB Gold In-Tube test (QFT-GIT)</td>
<td>ELISA</td>
<td>Cellestis, Carnegie, Australia</td>
<td>2007</td>
</tr>
<tr>
<td>T-SPOT.TB test</td>
<td>ELISPOT</td>
<td>Oxford Immunotech, UK</td>
<td>2008</td>
</tr>
</tbody>
</table>

QFT-GIT uses an enzyme-linked immunosorbent assay (ELISA) to measure the amount of IFN-γ released by T-cells in response to three M. tuberculosis specific antigens (ESAT-6, CFP-10 and TB7.7). It uses specially designed heparinized blood collection tubes that are coated with these highly specific antigens along with positive and negative control tubes (Figure 1). These specific antigens are absent from all BCG strains and most NTM (except M. szulgai, M. kansaii and M. marinum). A test is considered positive if the IFN-γ concentration of the TB-antigen tube is above the test cut-off (after subtracting the IFN-γ value in the negative control tube) [12].

T.SPOT.TB uses an enzyme-linked immunospot assay (ELISPOT) to detect increases in the number of T-cells that secrete IFN-γ in response to stimulation with ESAT-6 and CFP-10 antigens. Peripheral blood mononuclear cells are incubated with the control materials and the ESAT-6 and CFP-10 antigens in specialised sodium citrate, sodium, or lithium heparin tubes. The result is reported as the increase in the number of IFN-γ producing T cells (spot forming cells). A test is positive if the spot counts in the TB-antigen wells exceed a specific threshold relative to the control wells [12].

IGRAs are more specific than TST because the antigens do not cross react with BCG strains and most NTM (except M. szulgai, M. kansaii and M. marinum) [12]. IGRAs are also more sensitive, especially in immunocompromised individuals [11,12]. In a recent meta-analysis, IGRAs were found to have more specificity, higher positive predictive value (PPV), and higher negative predictive value (NPV) compared to the TST in the diagnosis of LTBI [39]. Unlike TST, IGRAs do not require a follow up visit to complete the testing process and results can be available within 24 to 48 hours [35].

Information on the performance of IGRAs in psoriasis patients is just accumulating. In a retrospective study in Switzerland, Laffitte et al [40] assessed 50 psoriasis patients who were screened for LTBI using both TST and T-Spot.TB test. A positive T-SPOT.TB test was found to correlate strongly with a diagnosis of LTBI [odds ratio (OR) = 7.43 (95% CI 1.38 to 39.9)], although there was poor agreement between the two tests (κ = 0.33, SD 0.13). Those who tested TST positive and IGRA negative did not receive anti-TB treatment and did not develop TB during a median period of 64 weeks (44-188 weeks) of anti-TNF treatment. In 2012, results of a comparative study of IGRAs and TST in patients with psoriasis and musculoskeletal inflammatory disorders...
demonstrated that IGRAs outperformed TST in both sensitivity and specificity [41]. These results led the authors to recommend that IGRAs should be used in place of TST as the optimal screening test for LTBI prior to anti-TNF therapy [40,41].

Like TST, IGRAs are not without limitations. They cannot distinguish between active TB disease and LTBI; they are expensive and not widely available. In addition, they have exacting requirements for blood collection and transportation, associated with a high percentage of indeterminate results and require specialized laboratory equipment and technical expertise to perform the assays [12,34,35,42]. Also, these tests have been in use for but a few years and the evidence to support their predictive value in the risk of progression from latent to active disease is still limited.

TST or IGRA?

Although it appears from the accumulating data that IGRAs may play an important role in LTBI detection, the lack of a gold standard for the diagnosis of LTBI and the lack of controlled trials comparing the TST and IGRAs make the understanding of their relative merits difficult. Most comparative studies have been retrospective and have been limited by low statistical power, heterogeneity in BCG status, differing underlying inflammatory conditions, and use of immunosuppressive therapies, all of which can affect the performance of the tests [43]. Moreover, the agreement between the TST and IGRAs, when applied simultaneously, has been found to be low [40,41,44,45]. In a large study in Germany, 1529 patients were evaluated for LTBI using TST and one form of IGRA (either TSPOT.TB or Quantiferon TB Gold); the concordance rate between the TST and IGRAs in this study was found to be only 89.5% (κ= 0.40 p< 0.001) [44]. Further, nearly 27 of 71 patients who had TST indurations of ≥15 mm and no prior history of BCG vaccination tested IGRA negative highlighting the potential pitfalls of relying on any single test as a screening tool for LTBI. Hsia et al [45] pooled data from five large RCTs of the TNF inhibitor golimumab in an autoimmune inflammatory disease population. Patients (n=2282) were evaluated for LTBI using TST and QFT-IT simultaneously. Like the previous study, entirely different sets of patients were identified by both tests and the concordance rates between the two tests was low even in individuals who had not undergone BCG vaccination, suggesting that the IGRA cannot as yet be used as a single test to rule out LTBI.

TST or IGRA?

Although it appears from the accumulating data that IGRAs may play an important role in LTBI detection, the lack of a gold standard for the diagnosis of LTBI and the lack of controlled trials comparing the TST and IGRAs make the understanding of their relative merits difficult. Most comparative studies have been retrospective and have been limited by low statistical power, heterogeneity in BCG status, differing underlying inflammatory conditions, and use of immunosuppressive therapies, all of which can affect the performance of the tests [43]. Moreover, the agreement between the TST and IGRAs, when applied simultaneously, has been found to be low [40,41,44,45]. In a large study in Germany, 1529 patients were evaluated for LTBI using TST and one form of IGRA (either TSPOT.TB or Quantiferon TB Gold); the concordance rate between the TST and IGRAs in this study was found to be only 89.5% (κ= 0.40 p< 0.001) [44]. Further, nearly 27 of 71 patients who had TST indurations of ≥15 mm and no prior history of BCG vaccination tested IGRA negative highlighting the potential pitfalls of relying on any single test as a screening tool for LTBI. Hsia et al [45] pooled data from five large RCTs of the TNF inhibitor golimumab in an autoimmune inflammatory disease population. Patients (n=2282) were evaluated for LTBI using TST and QFT-IT simultaneously. Like the previous study, entirely different sets of patients were identified by both tests and the concordance rates between the two tests was low even in individuals who had not undergone BCG vaccination, suggesting that the IGRA cannot as yet be used as a single test to rule out LTBI.

National guidelines currently vary in their recommendations on the use of TST and IGRA to screen for LTBI and these variations may be driven by the prevalent tuberculosis rates, BCG usage, and availability and affordability of the IGRAs in different parts of the world (Tables 3 and 4). Whereas the TST appears to be still favored in countries with high TB prevalence (where a positive TST would have a higher positive predictive value) and limited resources, the higher specificity and logistic convenience of the IGRAs appear to make these tests easy to adopt in low incidence countries with high BCG penetration and high resource settings [46]. A recent paper that reviewed 33 guidelines and 2 position papers from 25 countries and 2 supranational organizations found that there was lack of conclusive data to inform these guidelines and most (70%) did not use transparent and objective systems for guideline development [46].

Thus critical gaps in our knowledge remain on the optimal screening strategy and the cost-effectiveness of the various suggested approaches. Given the vulnerability of this group of patients to develop serious and disseminated forms of the disease, some authors recommend that it may be prudent, until robust evidence based algorithms emerge, to use both the TST and IGRA as a dual-testing strategy to maximise diagnostic sensitivity and patient safety [34,43,48]. This approach, however, may result in overestimated positivity leading to unwarranted therapy with toxic drugs, especially in populations with low prevalence of tuberculosis. Therefore, the best strategy currently remains unclear.

There is also uncertainty and lack of consensus on the frequency of rescreening in patients established on anti-TNF therapies. Whereas annual screening for LTBI in all patients on TNF-α inhibitor therapy using TST or QTF-G is recommended in the U.S.A [11], yearly screening with any IGRA is only recommended in high risk patients by the BAD guidelines [28].

Table 3. Comparison of recommendations of national guidelines for the diagnosis and treatment of LTBI prior to TNF antagonist therapy.
<table>
<thead>
<tr>
<th>Country</th>
<th>Selection of TST or IGRA</th>
<th>Treatment Regimen</th>
<th>Time Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK [59]</td>
<td>TST followed by IGRA if TST is positive</td>
<td>6H 3RH 4R</td>
<td>2 months</td>
</tr>
<tr>
<td>FRANCE [46,50]</td>
<td>IGRA alone</td>
<td>2RZ 3RH 9H</td>
<td>3 weeks</td>
</tr>
<tr>
<td>GERMANY [60]</td>
<td>IGRA alone</td>
<td>9H 4R</td>
<td>-</td>
</tr>
<tr>
<td>PORTUGAL [48]</td>
<td>Both TST and IGRA</td>
<td>9H</td>
<td>1 month</td>
</tr>
<tr>
<td>AUSTRALIA [61]</td>
<td>Either TST or IGRA</td>
<td>9H 4R</td>
<td>1-2 months</td>
</tr>
<tr>
<td>TBNET CONSSENSUS [49]</td>
<td>Both TST and IGRA</td>
<td>9-12H 3RH</td>
<td>1 month</td>
</tr>
</tbody>
</table>

**TST**: Tuberculin standard test; **IGRA**: Interferon Gamma Release Assay; **H**: isoniazid; **RH**: rifampicin plus isoniazid; **R**: rifampicin; **RZ**: rifampicin plus pyrazinamide

### Table 4. Centers of disease control and prevention guidelines on the selection of TST or IGRA for tuberculosis screening [12]

<table>
<thead>
<tr>
<th>Situations where the TST or IGRA may be used without preference</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Contact Investigation</td>
</tr>
<tr>
<td>• Periodic screening and surveillance programmes (e.g. in healthcare workers)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Situations where the TST is preferred but IGRA is acceptable</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Child &lt; 5 years</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Situations where IGRA is preferred but TST is acceptable</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Groups with low rates of return to have TST read at 48 hours.</td>
</tr>
<tr>
<td>• BCG vaccinated individuals</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Situations where both TST and IGRA may be considered</th>
</tr>
</thead>
<tbody>
<tr>
<td>• When either test is negative, but the risk of tuberculosis infection is high and outcome poor.</td>
</tr>
<tr>
<td>• When either test is positive, but the risk of tuberculosis infection is low.</td>
</tr>
<tr>
<td>• When the initial IGRA is indeterminate</td>
</tr>
</tbody>
</table>

**Chemoprophylaxis**

Individuals diagnosed with LTBI should receive appropriate chemoprophylaxis in accordance with local recommendations or guidelines (Table 3). Given the profound morbidity and associated mortality of TB associated with TNF inhibitor therapy, a low threshold for prophylactic therapy is recommended [48,49]. There is general agreement that the potential hepatotoxicity associated with isoniazid should not prevent patients from receiving treatment for LTBI [21,48]. Instead, patient education, clinical monitoring, and baseline and monthly monitoring of liver enzymes should be undertaken to evaluate possible adverse effects that may occur during the course of therapy [21,48]. In patients in whom hepatotoxicity seriously limits use, other validated, albeit less effective, rifampicin based regimens should be considered.

The optimal time delay for initiating TNF inhibitors after LTBI therapy has not been established and guidelines vary widely in their recommendations with suggested time frames ranging from a 3-week delay in the French guidelines [50], to completion of a full 9-month course of preventive therapy in the NPF guidelines [30] (Table 3). However, there seems to be consensus among most guidelines that if the clinical condition warrants early treatment, anti-TNF therapy can be commenced after completion of 1-2 months of LTBI therapy provided adherence and tolerance to therapy are ensured (Table 3).
Although appropriate treatment will prevent the development of active disease in a majority of patients, no regimen is wholly effective in preventing reactivation [30]. Numerous case reports and series showed development of clinically active TB despite strict adherence to prophylactic recommendations, suggesting that the risk of TB persists in spite of adequate prophylaxis [51-53]. Evidence from systematic reviews and clinical trials of the various regimens commonly used in LTBI therapy showed that the efficacy in preventing TB reactivation was 90% with a 9 month isoniazid regimen, 69% with a 6 month isoniazid daily regimen, 65% with a 4 month rifampicin regimen, and 65% with a 2 month regimen of rifampicin and pyrazinamide [54]. A meta-analysis of 11 RCTs of 6-12 months of isoniazid preventive therapy involving 73,375 patients found that isoniazid was effective in preventing the development of TB in only about 60% patients who complete therapy, suggesting that chemoprophylaxis may not be fully protective [55].

Apart from efficacy, poor adherence to therapy remains another barrier to effective chemoprophylaxis. Current data suggest that completion rates are less than 50% over 9 months of therapy [54]. Patient education, the use of incentives and directly observed therapy (DOT) may improve adherence and lead to higher rates of completion [21,54].

Constant vigilance for typical and atypical manifestations of active TB is necessary during and for 6 months after completion of anti-TNF therapy [11, 28]. If patients do develop active TB, TNF therapy should be withdrawn and the patients referred to an appropriate physician for adequate management. Cases of paradoxical aggravation of TB have been reported in patients withdrawn from anti-TNF treatment. This response has been attributed to the immune reconstitution following withdrawal of iatrogenic immunosuppression, defined as the Immune Reconstitution Inflammatory Syndrome (IRIS), and may require treatment with corticosteroids and NSAIDs [56,57].

**Conclusions**

The introduction of biologics and the efficacy demonstrated by the TNFα inhibitors in particular have revolutionized the treatment of moderate to severe psoriasis. Because of the important role TNF plays in containing TB infection, the use of TNF inhibitors increases the incidence of active TB in various populations. The monoclonal antibodies infliximab and adalimumab appear to be more heavily associated with the risk of reactivation than the soluble receptor etanercept. TB associated with TNF inhibitor therapy, unlike classical disease, is often disseminated, atypical, extra pulmonary, and life threatening. Although appropriate screening and treatment of LTBI will lower the risk of reactivation to a large extent, no chemoprophylactic regimen is completely protective. It has been suggested that adherence to solely TST based guidelines may overestimate the risk of LTBI in patients with moderate to severe psoriasis. Whereas the performance characteristics of IGRAs are seemingly superior to the TST, they are not without limitations. Generally, a clear consensus on the optimal screening strategy is still needed.

**References**


Winthrop KL. Serious infections with antirheumatic therapy: are biologics worse? Ann Rheum Dis. 2006 Nov; 65(Suppl 3): iii 54-7. PMID: 17038474


Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmunity Rev. 2008 Dec; 8(2): 147-52. PMID: 18706526


51. Calikoglu M, Sahin G, Aslan G. Two cases of tuberculosis complicating treatment with tumor necrosis factor-α inhibitors. Turkish Thoracic Journal. 2008 Sep; 9(3): 133-6


